{"id":25723,"date":"2023-11-24T13:12:02","date_gmt":"2023-11-24T07:42:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25723"},"modified":"2024-01-05T10:37:48","modified_gmt":"2024-01-05T05:07:48","slug":"cosentyx-for-hidradenitis-suppurativa-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment","title":{"rendered":"Novartis Cosentyx: First Biologic Hidradenitis Suppurativa Treatment After Almost Ten Years"},"content":{"rendered":"\n

While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis<\/strong> currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB\u2019s bimekizumab<\/strong>, recently approved as Bimzelx <\/strong>for plaque psoriasis treatment<\/a> and seeking approval for hidradenitis suppurativa treatment as well. On October 31, the FDA approved Cosentyx (secukinumab)<\/strong> to treat moderate to severe hidradenitis suppurativa in adults, marking the first approval of a new biologic for this skin condition in nearly a decade.<\/p>\n\n\n\n

Hidradenitis Suppurativa, recognized as Acne Inversa, is a complex dermatological disorder marked by the recurring development of painful nodules and suppuration, particularly in the axillary and groin regions. The absence of a definitive biological or pathological test necessitates a diagnosis based on clinical features and the chronic nature of the condition.<\/p>\n\n\n\n

As per DelveInsight estimates, the total prevalent cases of hidradenitis suppurativa<\/a> in the 7MM comprised approximately 6.2 million<\/strong> cases in 2022 and are projected to increase during the forecast period. In the US and EU, hidradenitis suppurativa is more common in females than males<\/strong>, but in Japan, it is the opposite, as, in Japan, males are more commonly affected than females. The highest proportion of hidradenitis suppurativa prevalent pool was observed in the 30\u201339 years age group<\/strong> among all the countries.<\/p>\n\n\n\n

\"Hidradenitis<\/a><\/figure>\n\n\n\n
\n

According to <\/em>Dr. Alexa B. Kimball, the lead investigator of the SUNSHINE and SUNRISE trials and a Professor of Dermatology at Harvard Medical School<\/em><\/strong>, the daily impact of hidradenitis suppurativa, along with the quest for symptom relief, can persist for years. This prolonged struggle often results in both physical and emotional scarring, which is painful and irreversible. The approval of this new treatment signifies a crucial breakthrough for numerous patients who have been grappling with limited therapeutic options.<\/em><\/p>\n<\/blockquote>\n\n\n\n

\n

\u201cHidradenitis suppurativa stands as one of the most challenging and draining skin conditions. The agony of its outbreaks can be incapacitating, hindering my ability to work or engage in social activities. It takes a toll on me both physically and emotionally, fostering feelings of anxiety, stress, and isolation,\u201d shared <\/em>Donna Atherton, EdD, Founder and Chief Mission Officer of the International Association of Hidradenitis Suppurativa Network (IAHSN)<\/em><\/strong>. \u201cThe approval of a new treatment option instills fresh hope for myself and the entire HS community, offering the prospect of relief from the burdens imposed by this disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n

The FDA granted approval for Cosentyx in the treatment of hidradenitis suppurativa<\/a> based on comprehensive analyses derived from the most extensive Phase III program in hidradenitis suppurativa history, known as SUNSHINE and SUNRISE<\/strong>. This groundbreaking study revealed that a greater percentage of patients receiving Cosentyx 300 mg, either biweekly or monthly, achieved a Hidradenitis Suppurativa Clinical Response (HiSCR50) compared to those on a placebo. The approved dosage for Cosentyx in hidradenitis suppurativa is 300 mg, administered every four weeks, with the flexibility to escalate to a biweekly schedule if the patient exhibits an inadequate response.<\/p>\n\n\n\n

In both the SUNSHINE and SUNRISE trials<\/strong>, assessing Cosentyx over 16 weeks (compared to a placebo) and a 52-week treatment period, the effectiveness of Cosentyx became evident as early as Week 2. The efficacy continued to improve through Week 16 and remained noticeable up to Week 52. The safety findings of Cosentyx in these trials for hidradenitis suppurativa were in line with its established safety profile observed in trials for plaque psoriasis, reinforcing the distinct safety profile of Cosentyx.<\/p>\n\n\n\n

\n

Victor Bult\u00f3, President of Novartis US<\/em><\/strong>, stated that Cosentyx delivers effective and long-lasting relief from hidradenitis suppurativa symptoms, enabling people with hidradenitis suppurativa to lead their lives with confidence. This approval for the sixth indication of Cosentyx underscores our unwavering commitment to transforming the landscape of medicine for individuals grappling with immunological diseases, with continued research in various conditions.<\/em><\/p>\n<\/blockquote>\n\n\n\n

Novartis has pinned its hopes on Cosentyx\u2019s approval for hidradenitis suppurativa treatment<\/a>, coupled with potential expansions into giant cell arteritis and lupus nephritis, to propel the medication into its next phase of growth. If all three indications prove successful, Cosentyx has the potential to generate an additional $2 billion<\/strong> in peak sales, according to Novartis. In the third quarter, Cosentyx recorded approximately $1.3 billion <\/strong>in sales, marking a 4% <\/strong>increase over the $1.27 billion<\/strong> achieved during the same period in 2022. Cumulatively, for the initial nine months of 2023, Cosentyx has amassed a total revenue of $3.7 billion<\/strong>.<\/p>\n\n\n\n

\"Cosentyx<\/figure>\n\n\n\n

Despite Novartis securing approval for Cosentyx in hidradenitis suppurativa, the drug may face stiff competition from UCB\u2019s bimekizumab<\/strong>, which recently presented data at the American Academy of Dermatology\u2019s annual meeting. The data indicated that bimekizumab\u2019s efficacy was \u201cincrementally better than\u201d Cosentyx, as it significantly outperformed the placebo in the proportion of patients achieving at least a 50% reduction in inflammatory lesions.<\/p>\n\n\n\n

Bimekizumab by UCB Biopharma<\/strong> is the first humanized monoclonal IgG1 antibody<\/strong> that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines. They are both co-expressed at sites of inflammation and have overlapping proinflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction.<\/p>\n\n\n\n

Despite encountering regulatory challenges, bimekizumab<\/strong>, now known as Bimzelx <\/strong>after securing approval for psoriasis treatment<\/a>, is gearing up for further regulatory milestones. In October, the company announced plans to swiftly submit applications for additional indications in the US, marking the next step in its regulatory journey.<\/p>\n\n\n\n

\"Hidradenitis<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

While another inflammatory biologic is making strides in the hidradenitis suppurativa treatment domain, Cosentyx by Novartis currently holds a significant lead. This advantage is crucial for Swiss Pharma, especially as dermatology experts anticipate strong competition from UCB\u2019s bimekizumab, recently approved as Bimzelx for plaque psoriasis treatment and seeking approval for hidradenitis suppurativa treatment as well. […]<\/p>\n","protected":false},"author":14,"featured_media":25724,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17358,20025,21470,423,20560,20561],"industry":[17225],"therapeutic_areas":[17237],"class_list":["post-25723","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-cosentyx","tag-hidradenitis-suppurativa","tag-hidradenitis-suppurativa-treatment","tag-novartis","tag-plaque-psoriasis-treatment","tag-psoriasis-treatment","industry-pharmaceutical","therapeutic_areas-dermatology"],"acf":[],"yoast_head":"\nCosentyx: First Biologic Hidradenitis Suppurativa Treatment<\/title>\n<meta name=\"description\" content=\"On October 31, FDA approved Cosentyx hidradenitis suppurativa treatment, marking first approval of new biologic in nearly a decade.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cosentyx: First Biologic Hidradenitis Suppurativa Treatment\" \/>\n<meta property=\"og:description\" content=\"On October 31, FDA approved Cosentyx hidradenitis suppurativa treatment, marking first approval of new biologic in nearly a decade.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-24T07:42:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-05T05:07:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/24130716\/cosentyx-for-hidradenitis-suppurativa-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cosentyx: First Biologic Hidradenitis Suppurativa Treatment","description":"On October 31, FDA approved Cosentyx hidradenitis suppurativa treatment, marking first approval of new biologic in nearly a decade.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment","og_locale":"en_US","og_type":"article","og_title":"Cosentyx: First Biologic Hidradenitis Suppurativa Treatment","og_description":"On October 31, FDA approved Cosentyx hidradenitis suppurativa treatment, marking first approval of new biologic in nearly a decade.","og_url":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-11-24T07:42:02+00:00","article_modified_time":"2024-01-05T05:07:48+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/24130716\/cosentyx-for-hidradenitis-suppurativa-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment","url":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment","name":"Cosentyx: First Biologic Hidradenitis Suppurativa Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/24130716\/cosentyx-for-hidradenitis-suppurativa-treatment.webp","datePublished":"2023-11-24T07:42:02+00:00","dateModified":"2024-01-05T05:07:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"On October 31, FDA approved Cosentyx hidradenitis suppurativa treatment, marking first approval of new biologic in nearly a decade.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/cosentyx-for-hidradenitis-suppurativa-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/24130716\/cosentyx-for-hidradenitis-suppurativa-treatment.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/24130716\/cosentyx-for-hidradenitis-suppurativa-treatment.webp","width":772,"height":482,"caption":"cosentyx-for-hidradenitis-suppurativa-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/24130716\/cosentyx-for-hidradenitis-suppurativa-treatment-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cosentyx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hidradenitis Suppurativa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hidradenitis Suppurativa Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Plaque Psoriasis treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Psoriasis treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cosentyx<\/span>","<span class=\"advgb-post-tax-term\">Hidradenitis Suppurativa<\/span>","<span class=\"advgb-post-tax-term\">Hidradenitis Suppurativa Treatment<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Plaque Psoriasis treatment<\/span>","<span class=\"advgb-post-tax-term\">Psoriasis treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 24, 2023","modified":"Updated on Jan 5, 2024"},"absolute_dates_time":{"created":"Posted on Nov 24, 2023 1:12 pm","modified":"Updated on Jan 5, 2024 10:37 am"},"featured_img_caption":"cosentyx-for-hidradenitis-suppurativa-treatment ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25723"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25723\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25724"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25723"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25723"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}